Published in Oncol Lett on August 27, 2014
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res (2004) 2.90
Targeted therapies for hepatocellular carcinoma. Gastroenterology (2011) 2.85
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol (2003) 2.08
Developmental regulation of insulin-like growth factor II mRNA in different rat tissues. J Biol Chem (1986) 1.44
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res (2009) 1.43
Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol (2013) 1.23
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res (2011) 1.15
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol (2009) 1.12
Growth patterns and interstitial invasion of small hepatocellular carcinoma. Pathol Int (1995) 1.09
Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype. Cancer Res (2002) 1.03
Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol (2013) 1.02
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int (2012) 0.95
Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media. Exp Ther Med (2010) 0.90
Insulin-like growth factor I receptor involvement in proliferation of NOR-P1 cells in serum-free media. J Cell Biochem (2012) 0.89
Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol (2006) 0.84
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway. PLoS One (2013) 0.82
Picropodophyllin suppresses the proliferation and invasion of hepatocellular carcinoma under serum starvation. Mol Med Rep (2011) 0.81
Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy. Clin Cancer Res (2013) 0.81
Frizzled-2: A potential novel target for molecular pancreatic cancer therapy. Oncol Lett (2013) 0.81
Anti-mitochondrial M2 antibody-positive autoimmune hepatitis. Exp Ther Med (2015) 0.79
SU11274 suppresses proliferation and motility of pancreatic cancer cells. Oncol Lett (2015) 0.77
2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncol Lett (2016) 0.75
Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithine. Oncol Lett (2017) 0.75
Introduction of plasmids into gastric cancer cells by endoscopic ultrasound. Oncol Lett (2017) 0.75
Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine. Oncol Lett (2017) 0.75
Higher serum uric acid levels and advanced age are associated with an increased prevalence of colorectal polyps. Biomed Rep (2015) 0.75
Short hairpin RNA of frizzled-2 suppresses the proliferation of hepatocellular carcinoma cells. Oncol Lett (2014) 0.75
FH535 suppresses the proliferation and motility of hepatocellular carcinoma cells. Int J Oncol (2015) 0.75
Diagnostic accuracy of diffusion-weighted whole-body imaging with background body signal suppression/T2-weighted image fusion for the detection of abdominal solid cancer. Exp Ther Med (2017) 0.75
Diagnosis of complications associated with acute cholecystitis using computed tomography and diffusion-weighted imaging with background body signal suppression/T2 image fusion. Exp Ther Med (2017) 0.75
Comparison of acute cholangitis with or without common bile duct dilatation. Exp Ther Med (2017) 0.75
Suppressive effects of 3-bromopyruvate on the proliferation and the motility of hepatocellular carcinoma cells. Oncol Rep (2015) 0.75
CCAAT/enhancer-binding protein α decreases the viability of gastric cancer cells. Oncol Lett (2017) 0.75
Hepatocyte selection medium-enriched hepatocellular carcinoma cells are positive for α-fetoprotein and CD44. Oncol Lett (2017) 0.75